Ren-Yuan Bai1, Verena Staedtke1, Charles M Rudin1, Fred Bunz1, Gregory J Riggins1. 1. Department of Neurosurgery (R.-Y.B., G.J.R.), Department of Neurology (V.S.); Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland (F.B.); Department of Thoracic Oncology, Memorial Sloan Kettering Cancer Center, New York, New York (C.M.R.).
Abstract
BACKGROUND: Medulloblastoma is the most common malignant brain tumor in children. Current standard treatments cure 40%-60% of patients, while the majority of survivors suffer long-term neurological sequelae. The identification of 4 molecular groups of medulloblastoma improved the clinical management with the development of targeted therapies; however, the tumor acquires resistance quickly. Mebendazole (MBZ) has a long safety record as antiparasitic in children and has been recently implicated in inhibition of various tyrosine kinases in vitro. Here, we investigated the efficacy of MBZ in various medulloblastoma subtypes and MBZ's impact on vascular endothelial growth factor receptor 2 (VEGFR2) and tumor angiogenesis. METHODS: The inhibition of MBZ on VEGFR2 kinase was investigated in an autophosphorylation assay and a cell-free kinase assay. Mice bearing orthotopic PTCH1-mutant medulloblastoma allografts, a group 3 medulloblastoma xenograft, and a PTCH1-mutant medulloblastoma with acquired resistance to the smoothened inhibitor vismodegib were treated with MBZ. The survival benefit and the impact on tumor angiogenesis and VEGFR2 kinase function were analyzed. RESULTS: We determined that MBZ interferes with VEGFR2 kinase by competing with ATP. MBZ selectively inhibited tumor angiogenesis but not the normal brain vasculatures in orthotopic medulloblastoma models and suppressed VEGFR2 kinase in vivo. MBZ significantly extended the survival of medulloblastoma models derived from different molecular backgrounds. CONCLUSION: Our findings support testing of MBZ as a possible low-toxicity therapy for medulloblastomas of various molecular subtypes, including tumors with acquired vismodegib resistance. Its antitumor mechanism may be partially explained by inhibition of tumor angiogenesis.
BACKGROUND:Medulloblastoma is the most common malignant brain tumor in children. Current standard treatments cure 40%-60% of patients, while the majority of survivors suffer long-term neurological sequelae. The identification of 4 molecular groups of medulloblastoma improved the clinical management with the development of targeted therapies; however, the tumor acquires resistance quickly. Mebendazole (MBZ) has a long safety record as antiparasitic in children and has been recently implicated in inhibition of various tyrosine kinases in vitro. Here, we investigated the efficacy of MBZ in various medulloblastoma subtypes and MBZ's impact on vascular endothelial growth factor receptor 2 (VEGFR2) and tumor angiogenesis. METHODS: The inhibition of MBZ on VEGFR2 kinase was investigated in an autophosphorylation assay and a cell-free kinase assay. Mice bearing orthotopic PTCH1-mutant medulloblastoma allografts, a group 3 medulloblastoma xenograft, and a PTCH1-mutant medulloblastoma with acquired resistance to the smoothened inhibitor vismodegib were treated with MBZ. The survival benefit and the impact on tumor angiogenesis and VEGFR2 kinase function were analyzed. RESULTS: We determined that MBZ interferes with VEGFR2 kinase by competing with ATP. MBZ selectively inhibited tumor angiogenesis but not the normal brain vasculatures in orthotopic medulloblastoma models and suppressed VEGFR2 kinase in vivo. MBZ significantly extended the survival of medulloblastoma models derived from different molecular backgrounds. CONCLUSION: Our findings support testing of MBZ as a possible low-toxicity therapy for medulloblastomas of various molecular subtypes, including tumors with acquired vismodegib resistance. Its antitumor mechanism may be partially explained by inhibition of tumor angiogenesis.
Authors: Louisa von Baumgarten; David Brucker; Anca Tirniceru; Yvonne Kienast; Stefan Grau; Steffen Burgold; Jochen Herms; Frank Winkler Journal: Clin Cancer Res Date: 2011-07-25 Impact factor: 12.531
Authors: Paul A Northcott; David T W Jones; Marcel Kool; Giles W Robinson; Richard J Gilbertson; Yoon-Jae Cho; Scott L Pomeroy; Andrey Korshunov; Peter Lichter; Michael D Taylor; Stefan M Pfister Journal: Nat Rev Cancer Date: 2012-12 Impact factor: 60.716
Authors: Michael D Taylor; Paul A Northcott; Andrey Korshunov; Marc Remke; Yoon-Jae Cho; Steven C Clifford; Charles G Eberhart; D Williams Parsons; Stefan Rutkowski; Amar Gajjar; David W Ellison; Peter Lichter; Richard J Gilbertson; Scott L Pomeroy; Marcel Kool; Stefan M Pfister Journal: Acta Neuropathol Date: 2011-12-02 Impact factor: 17.088
Authors: Michelle De Witt; Alexander Gamble; Derek Hanson; Daniel Markowitz; Caitlin Powell; Saleh Al Dimassi; Mark Atlas; John Boockvar; Rosamaria Ruggieri; Marc Symons Journal: Mol Med Date: 2017-04-05 Impact factor: 6.354
Authors: Michael Hu; Xin Yi Lei; Jon D Larson; Melissa McAlonis; Kyle Ford; Daniella McDonald; Krystal Mach; Jessica M Rusert; Robert J Wechsler-Reya; Prashant Mali Journal: Biomaterials Date: 2021-12-02 Impact factor: 15.304
Authors: Oliver Jonas; David Calligaris; Kashi Reddy Methuku; Michael M Poe; Jessica Pierre Francois; Frank Tranghese; Armen Changelian; Werner Sieghart; Margot Ernst; Daniel A Pomeranz Krummel; James M Cook; Scott L Pomeroy; Michael Cima; Nathalie Y R Agar; Robert Langer; Soma Sengupta Journal: J Biomed Nanotechnol Date: 2016-06 Impact factor: 4.099
Authors: Hisham F Bahmad; Darine Daher; Abed A Aljamal; Mohamad K Elajami; Kei Shing Oh; Juan Carlos Alvarez Moreno; Ruben Delgado; Richard Suarez; Ana Zaldivar; Roshanak Azimi; Amilcar Castellano; Robert Sackstein; Robert J Poppiti Journal: J Histochem Cytochem Date: 2021-06-24 Impact factor: 2.479